(ABC News) American pharmaceutical company Pfizer and its German partner BioNTech announced Friday that a booster dose of their bivalent COVID-19 vaccine performs better against two circulating versions of the omicron variant, compared with a booster shot of their original vaccine.According to a joint press release, updated data from a Phase 2-3 clinical trial shows the Pfizer-BioNTech bivalent vaccine produced antibody responses against the BA.4 and BA.5 omicron subvariants that were three- to four-fold higher, compared with the original formula, when measured in adults approximately one month after receiving a booster dose. The safety and tolerability profile of the bivalent booster remains favorable and similar to the original vaccine, Pfizer and BioNTech said.
Pfizer, BioNTech say bivalent COVID-19 booster shot performs better against BA.5 omicron subvariant
- Published Nov 4, 2022